Dr. Ramalingam Reviews the GALAXY-1 Trial Results
Suresh S. Ramalingam, MD, from the Winship Cancer Institute, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.
Suresh S. Ramalingam, MD, a professor of medical oncology at the Winship Cancer Institute of Emory University in Atlanta, Georgia, describes results from the phase II GALAXY-1 trial that explored the Hsp90 inhibitor ganetespib as a second-line treatment for patients with advanced lung adenocarcinoma.
The goal of the trial was to determine which patients benefited the most from treatment with ganetespib. Overall, when compared to docetaxel, ganetespib improved overall survival by 2.4 months. Moreover, Ramalingam notes, these outcomes were more pronounced in patients diagnosed at least 6 months prior to treatment, with an overall survival improvement of 4.3 months.
Read more about this study >>>
<<<
